NASDAQ$ANAB
Anaptysbio Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
AnaptysBio reported Q1 2026 net loss of $52.9M with collaboration revenue in 10-Q.
For the quarter ended March 31, 2026, AnaptysBio reported a net loss of $52.9 million versus $39.3 million a year ago, with revenue primarily from collaboration agreements as immunology antibodies advance.
- Net loss $52.9M.
- Collaboration and milestone revenue model.
- Immunology pipeline (e.g., rosnilimab).
- Higher loss on development spend.
Headline financials
Revenue & EPS history
Anaptysbio · Revenue · Quarterly
$25.6M
Forward guidance
Milestone and partnership economics support funding; no product revenue guide.
Tailwinds
- Strong balance of partnered and wholly owned assets.
- Potential milestone inflows.
Headwinds
- Losses increased YoY.
- Clinical and regulatory risks on lead programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-1.7%
Avg return
Earnings day
-1.5%
Avg return
5 days after
-2.2%
Avg return
30 days after
51%
20 / 39 earnings
Positive
+15.8%
Q4 2019
Best reaction
-71.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.7% | -7.0% | -20.1% | |
| Q4 2025 | +14.5% | +13.0% | +9.2% | |
| Q3 2025 | +3.5% | -2.2% | +27.7% | |
| Q1 2025 | +0.9% | +2.6% | +18.2% | |
| Q4 2024 | +4.8% | +2.1% | +15.5% | |
| Q3 2024 | +11.4% | +6.9% | +18.7% | |
| Q2 2024 | -2.1% | +0.9% | +13.3% | |
| Q1 2024 | -9.1% | -1.9% | -9.0% | |
| Q4 2023 | +5.1% | -5.4% | -10.6% | |
| Q3 2023 | +6.0% | -0.1% | -9.3% | |
| Q2 2023 | +1.3% | +1.6% | +6.5% | |
| Q1 2023 | -9.5% | -13.3% | -12.9% | |
| Q4 2022 | -1.4% | -5.1% | -12.6% | |
| Q3 2022 | +0.7% | +6.5% | -3.0% | |
| Q2 2022 | -6.2% | +6.2% | +7.0% | |
| Q1 2022 | -11.6% | -10.1% | -14.3% | |
| Q4 2021 | -3.5% | -5.4% | -14.6% | |
| Q3 2021 | +8.9% | +2.9% | -11.2% | |
| Q2 2021 | -1.0% | +0.4% | +15.0% | |
| Q1 2021 | +3.0% | +10.5% | +0.6% | |
| Q4 2020 | +8.4% | +4.2% | -19.9% | |
| Q3 2020 | -1.5% | -0.3% | -18.7% | |
| Q2 2020 | -5.6% | -8.4% | -14.4% | |
| Q1 2020 | +0.2% | +13.0% | +10.3% | |
| Q4 2019 | +15.8% | +21.9% | -11.0% | |
| Q3 2019 | -71.3% | -69.6% | -61.2% | |
| Q2 2019 | -1.4% | -5.2% | -20.5% | |
| Q1 2019 | -6.8% | -0.7% | -3.5% | |
| Q4 2018 | -1.6% | -4.4% | +1.8% | |
| Q3 2018 | -16.1% | -19.0% | -16.5% | |
| Q2 2018 | +4.6% | +6.8% | +10.2% | |
| Q1 2018 | +0.5% | +0.6% | -18.8% | |
| Q4 2017 | -6.6% | -9.1% | -26.6% | |
| Q3 2017 | +1.3% | +2.7% | +37.1% | |
| Q2 2016 | +0.8% | -5.2% | +46.0% | |
| Q2 2017 | +0.8% | -5.2% | +46.0% | |
| Q1 2016 | -1.1% | +0.2% | -15.9% | |
| Q4 2016 | -1.1% | +7.4% | -12.4% | |
| Q1 2017 | +2.5% | +7.4% | -12.4% | |
| Q3 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro